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Background: Intimal hyperplasia is a major cause of obstacle to patency after vein grafting. Several clinical trials revealed that peroxisome proliferators-activated receptor-γ ligand, pioglitazone exerts beneficial actions on cardiovascular complications.
Here, we investigated whether pioglitazone modulates intimal hyperplasia in an experimental rabbit autologous vein graft.
Methods:
Male Japanese white rabbits were randomly divided into two groups and were treated with or without pioglitazone as food admixture at a concentration of 0.01%.
One week later, each group underwent reversed autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone therapy was continued after surgery and until the time harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days after surgery. Two weeks after implantation, proliferative cells in neointima were identified by immunohistochemical staining with Ki-67 monoclonal antibody. To determine apoptotic cells, we also performed terminal transferase-mediated deoxyuride-5'-triphosphate nick-end labeling (TUNEL) staining.
Blood samples were collected at 28 days after implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were determined by western blotting analysis. Finally, we assessed adiponectin-related signaling pathway, AMP-activated protein kinase (AMPK) and extracellular signal-regulated kinase (ERK) in the grafted vein by Western blot analysis. Conclusions: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of graft failure after bypass grafting.
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